← SynDRA
FEZOLINETANT
SynDRA canonical compound SYN0038338 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TACR3 |
|---|
| Mechanism of action | neurokinin receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- TACR3 ANTAGONIST
- Neurokinin 3 receptor antagonist
- neurokinin receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- CYP3A4
- KCNH2
- TACR1
- TACR2
ATC classes
- G02C · OTHER GYNECOLOGICALS
Cross-references
Synonyms
- VEOZAH
- Veozah
- veozah
- ESN364
- ESN-364
- AS3472693-00
- A2693
- A-2693
- AS-3472693-00
- ES-256364
- Veoza
- ?ESN-364?
- 83VNE45KXX
- AC-36697
- AKOS040741724
- BDBM50112244
- CHEMBL3608680
- compound 3 (PMID:26191358)
- compound 3 [PMID:26191358]
- CS-7952
- D87169
- DTXSID601103615
- ESN-364ESN-364
- EX-A6226
- FEZOLINETANT [INN]
- Fezolinetant [USAN]
- FEZOLINETANT [WHO-DD]
- fezolinetantum
- GTPL10422
- HY-19632
- MS-25636
- Q27269455
- SCHEMBL16114810
- UNII-83VNE45KXX
- WHO 10205
- ESN 364
- RefChem:56330
- DTXCID901535295
Look up FEZOLINETANT in the interactive SynDRA portal →